Anti-FGF23 Ligand Dosing Using Phosphate and Vitamin D Feedback
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective methods to treat disorders related to abnormal phosphate metabolism, such as those associated with abnormal FGF23 signaling, and to evaluate the efficacy of such treatments.
Innovation Solution
Determine the dosing regimen of anti-FGF23 ligands based on the relationship between phosphate levels and regulated FGF23 levels during chronic administration, using PD parameters like serum phosphorus, Tmp/GFR, and vitamin D levels to administer anti-FGF23 ligands effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-FGF23 ligands are administered to treat disorders associated with abnormal phosphate metabolism, then phosphate levels and bone remodeling are improved, but the complexity of determining optimal dosing regimens increases
Solution Approach 1:
The patent employs feedback mechanisms by monitoring PD parameters (phosphate levels, Tmp/GFR, vitamin D levels) during chronic administration and using this information to determine and adjust dosing regimens. This feedback loop enables optimization of treatment efficacy while managing complexity through data-driven decision making.
Solution Approach 2:
The patent utilizes parameter changes by establishing relationships between PD parameters and FGF23 levels to determine dosing regimens. By monitoring changes in phosphate levels, Tmp/GFR, and vitamin D levels, the method optimizes dosing based on measurable parameter variations, transforming complex dosing determination into a systematic parameter-based approach.
2Stability of the object's composition
If chronic administration of anti-FGF23 ligands is used, then stable increase in phosphate levels is achieved, but the duration of action and monitoring requirements increase
Solution Approach 1:
The patent applies continuity of useful action by establishing chronic administration protocols that maintain stable phosphate levels over extended periods. The method ensures continuous therapeutic effect through regular dosing schedules while managing the duration through structured monitoring and adjustment protocols.
Solution Approach 2:
The patent uses feedback mechanisms to manage chronic administration by continuously monitoring PD parameters and adjusting dosing based on observed responses. This feedback enables maintenance of stable phosphate levels throughout chronic treatment while adapting to individual patient responses and changing conditions.
3Manufacturing precision
If PD parameters are monitored to determine dosing regimen, then treatment precision is improved, but the difficulty of detecting and measuring parameters increases
Solution Approach 1:
The patent employs intermediary measures by using PD parameters (phosphate levels, Tmp/GFR, vitamin D levels) as measurable surrogates to infer FGF23 activity and treatment response. These intermediary parameters provide accessible, quantifiable metrics that enable precise dosing determination without directly measuring FGF23 levels, thereby reducing measurement difficulty while maintaining dosing precision.
Data Source
AI summary
The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.